David Steensma, Chief Medical Officer (CMO) at Ajax Therapeutics, shared Ajax Therapeutics’s post on LinkedIn, adding:
“We are happy at Ajax Therapeutics to have recently been granted Orphan Drug Designation by FDA for AJ1-11095, the first Type II JAK2 inhibitor to enter the clinic, and look forward to sharing trial results in patients with myelofibrosis with the hematology/MPN community in 2026.”
Quoting Ajax Therapeutics’s post:
“Today we announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation to AJ1-11095 for the treatment of myelofibrosis, a debilitating blood cancer that affects approximately 20,000 patients in the U.S.
AJ1-11095 is a first-in-class Type II JAK2 inhibitor currently in a Phase 1 study for the treatment of patients with myelofibrosis, previously treated with a Type I JAK2 inhibitor.
More posts featuring David Steensma.